5 Analysts Assess Quest Diagnostics: What You Need To Know
Portfolio Pulse from Benzinga Insights
Five analysts have recently published ratings on Quest Diagnostics (NYSE:DGX), with a mix of bullish, indifferent, and somewhat bullish sentiments. The average 12-month price target has increased to $157.0, with a high estimate of $165.00 and a low estimate of $153.00. Analysts have raised their price targets and ratings, reflecting positive sentiment towards the company's financial performance and market position.
July 24, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics has received mixed analyst ratings, with a recent increase in the average 12-month price target to $157.0. Analysts have raised their ratings and price targets, indicating positive sentiment towards the company's financial performance and market position.
The increase in the average 12-month price target and the raised ratings from multiple analysts suggest a positive short-term impact on Quest Diagnostics' stock price. The company's strong financial performance and market position further support this sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100